Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02644967
Title A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Idera Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
The University of Arizona Cancer Center Tucson Arizona 85719 United States Details
Moffitt Cancer Center Research Institute Tampa Florida 33612 United States Details
University of Iowa Hospitals and Clinics Iowa City Iowa 52242 United States Details
University of Kansas Cancer Center Westwood Kansas 66205 United States Details
Roswell Park Cancer Institute Buffalo New York 14263 United States Details
Icahn School Of Medicine at Mount Sinai New York New York 10029 United States Details
Gabrail Cancer Center Canton Ohio 44718 United States Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
University of Utah- Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field